Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Endometriosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2017

Login to access report north_east
Contact sales account_box

Pelvic pain is the main clinical manifestation associated with endometriosis, a disorder caused by endometrial tissues growing outside the uterus. Pain relievers, hormonal contraceptives, aromatase inhibitors, androgenic agents, and gonadotropin-releasing hormone (Gn-RH) agonists are currently used to manage endometriosis-associated pelvic pain. However, more-efficacious and more easily administered medical options remain a high unmet need. The launches of second-generation, orally administered Gn-RH antagonists will significantly expand the endometriosis therapeutic market by 2026.

Questions Answered:

  • Endometriosis usually affects women of reproductive age. How large are the diagnosed prevalent endometriosis populations in the United States and EU5 (France, Germany, Italy, Spain, and the United Kingdom)? What percentage of diagnosed endometriosis patients received drug treatment in 2016? How will the drug-treated rate change in 2026?
  • We expect that by 2024, three Gn-RH antagonists will be launched. What clinical role will second-generation, oral Gn-RH antagonist therapies play in the management of endometriosis? What are clinical advantages of Gn-RH antagonists compared with Gn-RH agonists?
  • AbbVie’s elagolix is the most advanced oral Gn-RH antagonist in development. How will elagolix be differentiated from other emerging Gn-RH antagonists—relugolix and OBE-2109 in the endometriosis therapeutic market?Which emerging Gn-RH antagonists will enjoy the greatest clinical and commercial success by 2026?

Scope:

Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Six country-specific interviews with endometriosis specialists.

Epidemiology: Diagnosed and drug-treated prevalent cases.

Emerging therapies: Phase III/PR: 2; Phase II: 3; coverage of select preclinical and Phase I products.

Market forecast: Drug-level sales and patient share of key endometriosis therapies in 2026.  

Key companies:  AbbVie, Bayer, Myovant, ObsEva, Repros.

Key drugs: elagolix, relugolix, OBE-2109, leuprolide, telapristone, vilaprisan.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east